A5080169213- Liver Disease Diagnosis and Treatment
- Liver Disease and Transplantation
- Hepatitis C virus research
- Hepatitis B Virus Studies
- Organ Transplantation Techniques and Outcomes
- Hepatitis Viruses Studies and Epidemiology
- COVID-19 Clinical Research Studies
- Liver Diseases and Immunity
- Drug-Induced Hepatotoxicity and Protection
- Hepatocellular Carcinoma Treatment and Prognosis
- Alcohol Consumption and Health Effects
- Systemic Sclerosis and Related Diseases
- Systemic Lupus Erythematosus Research
- Hormonal Regulation and Hypertension
- Trace Elements in Health
- Gastrointestinal Bleeding Diagnosis and Treatment
- COVID-19 and healthcare impacts
- Biochemical effects in animals
- Liver physiology and pathology
- Growth Hormone and Insulin-like Growth Factors
- SARS-CoV-2 and COVID-19 Research
- Diet and metabolism studies
- High Altitude and Hypoxia
- Electrolyte and hormonal disorders
- Cerebral Venous Sinus Thrombosis
Medical University of Vienna
2019-2025
Medizinische Hochschule Hannover
2024
University of Vienna
2022
Laboratoire des Sciences de l’Information et de la Communication
2020
Montavid Thermodynamic Research Group
2020
Comprehensive Cancer Center Vienna
2020
•Progression of portal hypertension severity (reflected by HVPG) occurs mostly across compensated ACLD stages.•Systemic inflammation CRP and IL-6 levels) substantially increases only decompensated ACLD.•IL-6 levels are independent predictors first decompensation in death/liver transplantation ACLD. Background & AimsDistinct prognostic stages advanced chronic liver disease (ACLD) defined (PH) the presence/absence clinical complications. We characterised degree dysfunction, PH, systemic...
Liver stiffness measurements (LSMs) provide an opportunity to monitor liver disease progression and regression noninvasively. We aimed determine the prognostic relevance of LSM dynamics over time for liver-related events death in patients with chronic disease.Patients undergoing 2 or more reliable LSMs at least 180 days apart were included this retrospective cohort study stratified baseline (BL) as nonadvanced (non-ACLD, BL-LSM < 10 kPa), compensated ACLD (cACLD; ≥ decompensated ACLD. Data...
Background & Aims: Clinically-significant portal hypertension (CSPH) in liver cirrhosis patients can lead to refractory ascites. A transjugular-intrahepatic-portosystemic shunt (TIPS) treats CSPH but may cause overt hepatic encephalopathy (oHE). Our aim was determine the optimal reduction of pressure gradient (PPG) via TIPS control ascites without raising oHE risk. Approach: This multicenter study screened 1509 from three European centers (Hannover, Vienna, Hamburg) undergoing...
Systemic inflammation promotes the development of clinical events in patients with advanced chronic liver disease (ACLD). We assessed whether (1) non-selective beta blocker (NSBB) treatment initiation impacts biomarkers systemic and (2) these changes predict complications mortality.Biomarkers inflammation, that is, white blood cell count (WBC), C reactive protein (CRP), interleukin-6 (IL-6) procalcitonin (PCT) were determined at sequential hepatic venous pressure gradient (HVPG) measurements...
Abstract Background and Aims Cholestasis is associated with disease severity worse outcome in COVID‐19. Cases of secondary sclerosing cholangitis (SSC) after severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) infection have been described. Approach Results Hospitalized patients COVID‐19 between 03/2020 07/2021 were included. Patients stratified as having (i) no chronic liver (CLD), (ii) non‐advanced CLD (non‐ACLD), or (iii) advanced (ACLD). non–COVID‐19 pneumonia matched to a...
Bulevirtide (BLV) blocks the uptake of hepatitis D virus (HDV) into hepatocytes via sodium/bile acid cotransporter NTCP. BLV was conditionally approved by EMA but real-life data on efficacy are limited.Patients were treated with monotherapy. Patients who did not achieve further decreases in HDV-RNA after 24 weeks offered PEG-IFN as an add-on therapy a response-guided manner.Twenty-three patients (m: 10, f: 13; mean age: 47.9 years, cirrhosis: 16; median ALT: 71 IU/ml; HDV-RNA: 2.1 × 105...
Baveno VII proposed liver stiffness measurement (LSM)/platelet count (PLT)-based criteria ('ruled out,' LSM ≤15 kPa plus PLT ≥150 G/L; 'ruled in': ≥25 kPa) for clinically significant portal hypertension (CSPH) in compensated advanced chronic disease (cACLD). However, a substantial proportion of patients remains 'unclassified.'Patients with evidence cACLD (LSM ≥10 undergoing hepatic venous pressure gradient (HVPG) at the Vienna General Hospital 2004 to 2021 (derivation [2004-2016], n = 221;...
Although ascites is the most frequent first decompensating event in cirrhosis, clinical course after as
Removing the primary aetiological factor in decompensated cirrhosis may lead to a restoration of hepatic function. In this study, we investigated clinical implications recompensation and subsequent survival patients with alcohol-related cirrhosis.The rate was evaluated persistent alcohol abstinence undergoing venous pressure gradient (HVPG) measurement. Recompensation defined according Baveno VII criteria as resolution ascites encephalopathy, absence variceal bleeding improvement liver...
The Billroth IV consensus was developed during a meeting of the Austrian Society Gastroenterology and Hepatology (ÖGGH) Interventional Radiology (ÖGIR) held on 26th November 2022 in Vienna.Based international recommendations considering recent landmark studies, provides guidance regarding diagnosis management portal hypertension advanced chronic liver disease.
Background and AimsNon-invasive tests (NIT) for assessing the probability of clinically significant portal hypertension (CSPH) including ANTICIPATE±NASH models based on liver stiffness measurement (LSM), platelet count (PLT)±body mass index (BMI), von Willebrand factor antigen (VWF) to PLT ratio (VITRO) have fundamentally changed management compensated advanced chronic disease (cACLD). However, their prognostic utility has not been compared head-to-head against hepatic venous pressure...
Chronic hepatitis D is the most debilitating form of viral frequently progressing to cirrhosis and subsequent decompensation. However, HDV entry inhibitor bulevirtide only approved for antiviral treatment patients with compensated disease. We aimed analysis real-world data on off-label use in setting decompensated liver cirrhosis.
Baveno VII has defined a clinically significant (i.e., prognostically meaningful) decrease in liver stiffness measurement (LSM) cACLD as of ≥20% associated with final LSM <20 kPa or any to <10 kPa. However, these rules have not yet been validated against direct clinical endpoints.
Background & AimsNonselective beta blockers (NSBBs) exert beneficial effects beyond lowering hepatic venous pressure gradient (HVPG), which may be particularly relevant in patients with decompensated cirrhosis (DC), whom bacterial translocation and bacterial-induced systemic inflammation drive the development of complications such as acute-on-chronic liver failure (ACLF). We evaluated whether NSBB-related changes von Willebrand factor (VWF) serve a biomarker for these effects.MethodsIn this...
•Factor VIII/protein C (FVIII/PC) ratio has prognostic value in advanced chronic liver disease.•This may be explained by the link between FVIII/PC and pathophysiological mechanisms promoting disease.•FVIII/PC was not associated with development of bleeding or thrombotic events.•Thus, should mistaken as evidence that hypercoagulability is a driver disease progression. Background & AimsIt been suggested procoagulant factor VIII to anticoagulant protein reflects hemostatic equilibrium....
Carvedilol induces stronger decreases in hepatic venous pressure gradient (HVPG) than conventional nonselective β-blockers (ie, propranolol). Limited data exist on the efficacy of carvedilol secondary prophylaxis variceal bleeding.Patients undergoing paired HVPG measurements for guiding with either or propranolol were included this retrospective analysis. All patients also underwent band ligation. Changes and systemic hemodynamics compared between 2 groups. Long-term follow-up rebleeding,...
Ammonia levels predicted hospitalisation in a recent landmark study not accounting for portal hypertension and systemic inflammation severity. We investigated (i) the prognostic value of venous ammonia (outcome cohort) liver-related outcomes while these factors (ii) its correlation with key disease-driving mechanisms (biomarker cohort).(i) The outcome cohort included 549 clinically stable outpatients evidence advanced chronic liver disease. partly overlapping biomarker comprised 193...
•Complement factors, immunoglobulins, and acute-phase proteins are dysregulated in patients with advanced chronic liver disease (ACLD), correlate severity, indicate alterations of innate adaptive immunity.•Low complement C3c levels independently predicted decompensation or liver-related death ACLD.•High IgG-1 the incidence infections ACLD. Background & AimsCirrhosis-associated immune dysfunction (CAID) affects both immunity. This study investigated system, their prognostic relevance...
Background and AimsNon-invasive tests (NIT) for clinically significant portal hypertension (CSPH) in compensated advanced chronic liver disease (cACLD) lack validation patients infected with hepatitis D virus (HDV).MethodsHDV-cACLD (LSM ≥10 kPa or histological METAVIR F3/F4 fibrosis) who underwent paired HVPG NIT assessment at Medical University of Vienna Hannover School between 2013 2023 were retrospectively included.Liver stiffness measurement (LSM), von Willebrand factor to platelet count...
Summary Background and Aims We aimed to characterise insulin‐like growth factor‐1 (IGF‐1) signalling in patients with advanced chronic liver disease (ACLD). Methods Consecutive undergoing hepatic venous pressure gradient [HVPG] measurement were prospectively included. Clinical stages defined as follows: probable ACLD (pACLD): stiffness ≥10 kPa HVPG ≤5 mmHg, S0: mild PH (HVPG 6–9 mmHg), S1: clinically significant (CSPH), S2: CSPH varices, S3: past variceal bleeding, S4: past/current...